Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 4/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713231 | 0.90 | NNMT (0.49) | NNMTRETMGLLGPR183KCNH2 | |
| SCHEMBL20071400 | 0.88 | NNMT (0.43) | NNMTRETMGLLGPR183KCNH2 | |
| SCHEMBL20152350 | 0.87 | RET (0.47) | NNMTRETMGLLGPR183KCNH2 | |
| SCHEMBL20148719 | 0.87 | HRH3 (0.44) | NNMTRETMGLLGPR183KCNH2 | |
| SCHEMBL23555184 | 0.83 | RET (0.41) | NNMTRETMGLLGPR183KCNH2 | |
| SCHEMBL20070454 | 0.77 | RET (0.52) | RETGPR183TACR3 | |
| SCHEMBL20962682 | 0.77 | RET (0.44) | NNMTRETMGLLGPR183KCNH2 | |
| SCHEMBL18390346 | 0.77 | NNMT (0.49) | NNMTRETMGLLGPR183KCNH2 | |
| SCHEMBL20962681 | 0.77 | NNMT (0.46) | NNMTRETMGLLGPR183KCNH2 | |
| SCHEMBL18390347 | 0.77 | NNMT (0.46) | NNMTRETMGLLGPR183KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| US-10953005-B1 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2019-06-20 | — | — | US | disclosed |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | NNMT 2639/4885RET 1/4885MGLL 4881/4885 |
| US-10953005-B1 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | NNMT 2639/4885RET 1/4885MGLL 4881/4885 |
| US-20190183886-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | NNMT 2639/4885RET 1/4885MGLL 4881/4885 |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | NNMT 2639/4885RET 1/4885MGLL 4881/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | NNMT 2639/4885RET 1/4885MGLL 4881/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | NNMT 2639/4885RET 1/4885MGLL 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.